TW200528451A - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
TW200528451A
TW200528451A TW093132291A TW93132291A TW200528451A TW 200528451 A TW200528451 A TW 200528451A TW 093132291 A TW093132291 A TW 093132291A TW 93132291 A TW93132291 A TW 93132291A TW 200528451 A TW200528451 A TW 200528451A
Authority
TW
Taiwan
Prior art keywords
diazospiro
isobutoxybenzyl
decane
undecane
group
Prior art date
Application number
TW093132291A
Other languages
English (en)
Chinese (zh)
Inventor
Stephen Connolly
Igor Shamovsky
Hakan Bladh
Annea Lisius
Hazel Joan Dyke
Den Heuvel Marco Van
Stephen Price
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29546627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200528451(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200528451A publication Critical patent/TW200528451A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
TW093132291A 2003-10-23 2004-10-22 Novel compounds TW200528451A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302811A SE0302811D0 (sv) 2003-10-23 2003-10-23 Novel compounds

Publications (1)

Publication Number Publication Date
TW200528451A true TW200528451A (en) 2005-09-01

Family

ID=29546627

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093132291A TW200528451A (en) 2003-10-23 2004-10-22 Novel compounds

Country Status (17)

Country Link
US (1) US20070249648A1 (cg-RX-API-DMAC7.html)
EP (1) EP1678178A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509141A (cg-RX-API-DMAC7.html)
KR (1) KR20060088557A (cg-RX-API-DMAC7.html)
CN (1) CN1898239A (cg-RX-API-DMAC7.html)
AR (1) AR046600A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004284028B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415613A (cg-RX-API-DMAC7.html)
CA (1) CA2542226A1 (cg-RX-API-DMAC7.html)
IL (1) IL174698A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004300A (cg-RX-API-DMAC7.html)
NO (1) NO20062335L (cg-RX-API-DMAC7.html)
SE (1) SE0302811D0 (cg-RX-API-DMAC7.html)
TW (1) TW200528451A (cg-RX-API-DMAC7.html)
UY (1) UY28572A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005040167A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603174B (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
JP4845873B2 (ja) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
WO2006107252A1 (en) * 2005-04-04 2006-10-12 Astrazeneca Ab Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
CN101155812A (zh) * 2005-04-04 2008-04-02 阿斯利康(瑞典)有限公司 新二氮杂螺烷和它们治疗ccr8介导的疾病的用途
EP1869044A1 (en) * 2005-04-04 2007-12-26 AstraZeneca AB Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
GB0514018D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
CA2669736C (en) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
MX2008015696A (es) * 2006-06-09 2009-02-10 Icos Corp Acidos fenil aceticos sustituidos como antagonistas de dp-2.
KR20090030347A (ko) * 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
EP2061791A1 (en) 2006-09-15 2009-05-27 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
KR20090071589A (ko) 2006-09-15 2009-07-01 쉐링 코포레이션 통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
CN101534822A (zh) * 2006-09-15 2009-09-16 先灵公司 治疗疼痛、糖尿病和脂质代谢紊乱
WO2008099165A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Piperidine derivatives and their use for treatment of ccr8 mediated diseases
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010151815A2 (en) * 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
PL2547679T3 (pl) 2010-03-19 2016-02-29 Pfizer Pochodne 2,3-dihydro-1H-inden-1-ylo-2,7-diazaspiro[3.5]nonanu i ich zastosowanie jako antagonistów lub odwrotnych agonistów receptora greliny
WO2013066718A2 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
AU2013272288B2 (en) * 2012-06-08 2018-01-18 The United States Government As Represented By The Department Of Veterans Affairs FBXO3 inhibitors
EA201492223A1 (ru) * 2012-06-13 2015-03-31 Ф. Хоффманн-Ля Рош Аг Новые диазаспироциклоалканы и азаспироциклоалканы
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9776979B2 (en) * 2013-09-26 2017-10-03 Sanford-Burnham Medical Research Institute EBI2 modulators
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
US10562869B2 (en) 2014-03-17 2020-02-18 Remynd Nv Oxadiazole compounds
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
SG11201607839UA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX382355B (es) 2015-04-10 2025-03-13 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
JP6832914B2 (ja) 2015-07-31 2021-02-24 ファイザー・インク Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MA42919A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
KR20240113606A (ko) 2015-11-16 2024-07-22 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
CA3050625C (en) 2017-01-20 2021-07-20 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
CN110198944A (zh) 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CR20190423A (es) 2017-03-16 2019-11-01 Hoffmann La Roche Nuevos compuestos biciclícos como inhibidores dobles de atx/ca
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
WO2020028706A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
AR116020A1 (es) 2018-09-03 2021-03-25 Bayer Ag COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
CN113207291A (zh) * 2018-10-24 2021-08-03 亚瑞克西斯制药公司 2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂
WO2022000443A1 (en) * 2020-07-03 2022-01-06 Nanjing Immunophage Biotech Co., Ltd. Methods and compositions for targeting tregs using ccr8 inhibitors
JP2024505261A (ja) 2021-01-29 2024-02-05 セディラ・セラピューティクス・インコーポレイテッド Ｃｄｋ２阻害剤およびその使用方法
CN117561058A (zh) 2021-06-26 2024-02-13 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
CA3235270A1 (en) * 2021-10-13 2023-04-20 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
AR131211A1 (es) 2022-11-30 2025-02-26 Idorsia Pharmaceuticals Ltd Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010201A (en) * 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
US4263317A (en) * 1979-09-06 1981-04-21 Hoechst-Roussel Pharmaceuticals, Inc. Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
BR9908351A (pt) * 1998-02-04 2001-11-20 Banyu Pharma Co Ltd Compostos, processo para a preparação dosmesmos, e, composição farmacêutica
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
US7560546B2 (en) * 2002-08-09 2009-07-14 Merck & Co., Inc. Tyrosine kinase inhibitors
US20070021498A1 (en) * 2004-10-14 2007-01-25 Nafizal Hossain Novel tricyclic spiroderivatives as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
KR20060088557A (ko) 2006-08-04
CA2542226A1 (en) 2005-05-06
UY28572A1 (es) 2005-05-31
ZA200603174B (en) 2007-03-28
NO20062335L (no) 2006-07-19
CN1898239A (zh) 2007-01-17
MXPA06004300A (es) 2006-06-05
AU2004284028B2 (en) 2008-03-06
AU2004284028A1 (en) 2005-05-06
US20070249648A1 (en) 2007-10-25
AR046600A1 (es) 2005-12-14
WO2005040167A1 (en) 2005-05-06
EP1678178A1 (en) 2006-07-12
BRPI0415613A (pt) 2006-12-05
SE0302811D0 (sv) 2003-10-23
IL174698A0 (en) 2006-08-20
JP2007509141A (ja) 2007-04-12

Similar Documents

Publication Publication Date Title
TW200528451A (en) Novel compounds
ES2650312T3 (es) Derivados de quinazolinona útiles como moduladores FGFR quinasa
ES2528269T3 (es) Azaindazoles
RS64055B1 (sr) Heterociklična jedinjenja kao imunomodulatori
CN105121443B (zh) 蛋白激酶抑制剂
KR20150133172A (ko) Mk2 억제제 및 이의 용도
KR20080043396A (ko) 신규 디아자스피로알칸 및 ｃｃｒ８ 매개성 질환의 치료를위한 그의 용도
TW201408666A (zh) 新穎化合物
TW200815434A (en) Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases
JP2009531357A (ja) 血管内皮リパーゼの阻害剤としてのアゾロピリジン−３−オン誘導体
TW200800908A (en) Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CN101621931A (zh) 杂芳基酰胺衍生物
RS57139B1 (sr) Novi biciklični derivati dihidrohinolin-2-ona
JP2010523668A (ja) Ｐ２ｘ７拮抗薬としてのヘテロアリールアミド類似体
KR20140084063A (ko) Fgfr 키나제의 억제를 통한 항암 벤조피라진
TW201121966A (en) Fused heterocyclic compounds as orexin receptor modulators
TW200904804A (en) Imidazolidinecarboxamide derivatives as inhibitors of lipases and phospholipases
TW200800920A (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
CA2875389C (en) 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
CN101163683A (zh) 用于治疗细胞因子疾病的4-氧代喹唑啉-3-基苯甲酰胺衍生物
CN104926788A (zh) 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN117285485B (zh) 一种双磺酰胺类衍生物及其制备方法和应用
WO2004022540A2 (en) Pyridazinone and pyridone derivatives as adenosine antagonists
ME00958B (me) Triazolo[1,5-a] kvinolini kao ligandi adenozin a3 receptora